Sentinel node biopsy in clinical stage I testicular cancer enables early detection of occult metastatic disease.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 30417511.
- Also identified by DOI 10.1111/bju.14618 and PMC identifier 6850062.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To report the long-term results of the sentinel node (SN) approach in patients with clinical stage I testicular tumours in our facility. We conducted an analysis of 27 consecutive patients suspected of clinical stage I testicular germ cell tumour (TGCT) and treated with an SN procedure at our tertiary referral centre. SNs were identified using lymphoscintigraphy with or without single-photo-emission computed tomography with CT (SPECT/CT). Patients underwent laparoscopic retroperitoneal SN excision with inguinal orchiectomy. Patients with a tumour-positive SN underwent adjuvant treatment. Follow-up was conducted according to then-current guidelines. In two patients, no SNs were visualized on scintigraphy. In the remaining 25 patients, a median (range) of 3 (1-4) SNs per patient were removed. Two patients showed no malignancy on histopathological examination of the testis. Of the 23 patients diagnosed with TGCT (16 seminomas, seven non-seminomas), three (13.0%) had occult metastatic disease. All 23 patients were without evidence of disease at a median (range) follow-up of 63.9 (29.0-143.4) months. The SN procedure allows early identification of patients with occult metastatic disease in clinical stage I TGCT, enabling early treatment.
Medical subject headings
- Sentinel Lymph Node Biopsy
- Testicular Neoplasms